Replimune Group (NASDAQ:REPL) Reaches New 1-Year High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $16.33 and last traded at $15.8030, with a volume of 99136 shares changing hands. The stock had previously closed at $15.67.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Tuesday, June 30th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Replimune Group Price Performance

The firm has a fifty day moving average of $12.00 and a 200 day moving average of $8.45. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $1.46 billion, a P/E ratio of -4.95 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insider Activity at Replimune Group

In related news, CFO Emily Luisa Hill sold 11,448 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the transaction, the chief financial officer owned 225,108 shares in the company, valued at $2,919,650.76. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the sale, the insider owned 224,215 shares in the company, valued at $2,908,068.55. This represents a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock valued at $1,038,364 over the last ninety days. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

Several large investors have recently modified their holdings of REPL. Quantinno Capital Management LP boosted its position in Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after purchasing an additional 96,188 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Replimune Group during the 1st quarter valued at about $921,000. Montanova Capital LLC grew its stake in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after purchasing an additional 168,000 shares during the period. EcoR1 Capital LLC purchased a new stake in shares of Replimune Group during the 1st quarter valued at about $7,650,000. Finally, Deutsche Bank AG purchased a new stake in shares of Replimune Group during the 2nd quarter valued at about $857,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.